

## BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
<b>COMMON STOCKS<sup>†</sup> - 99.9%</b>					
<b>BIOTECHNOLOGY - 74.4%</b>					
Amgen, Inc.	64,828	\$ 12,544,866			
Gilead Sciences, Inc.	162,729	10,313,764			
Celgene Corp.*	98,937	9,824,444			
Illumina, Inc.*	25,553	7,773,734			
Vertex Pharmaceuticals, Inc.*	45,368	7,686,246			
Biogen, Inc.*	32,777	7,631,141			
Regeneron Pharmaceuticals, Inc.*	23,018	6,385,193			
Alexion Pharmaceuticals, Inc.*	54,878	5,374,751			
Seattle Genetics, Inc.*	55,888	4,772,835			
Incyte Corp.*	61,182	4,541,540			
BioMarin Pharmaceutical, Inc.*	56,719	3,822,861			
Exact Sciences Corp.* <sup>1</sup>	41,240	3,726,859			
Alnylam Pharmaceuticals, Inc.*	42,430	3,412,221			
Ionis Pharmaceuticals, Inc.*	56,368	3,377,007			
Sage Therapeutics, Inc.*	20,116	2,822,074			
Exelixis, Inc.*	143,088	2,530,511			
ACADIA Pharmaceuticals, Inc.*	70,269	2,528,981			
Bluebird Bio, Inc.* <sup>1</sup>	26,900	2,469,958			
Medicines Co.*	48,486	2,424,300			
Spark Therapeutics, Inc.*	23,036	2,234,031			
United Therapeutics Corp.*	26,016	2,074,776			
FibroGen, Inc.*	55,217	2,041,925			
Nektar Therapeutics*	111,741	2,035,362			
Amarin Corporation plc ADR* <sup>1</sup>	127,480	1,932,597			
Ultragenyx Pharmaceutical, Inc.*	42,700	1,826,706			
Intercept Pharmaceuticals, Inc.* <sup>1</sup>	25,749	1,708,704			
Myriad Genetics, Inc.*	59,463	1,702,426			
Immunomedics, Inc.*	123,406	1,636,363			
PTC Therapeutics, Inc.*	47,670	1,612,199			
Ligand Pharmaceuticals, Inc. — Class B*	15,581	1,550,933			
REGENXBIO, Inc.*	35,520	1,264,512			
<b>Total Biotechnology</b>		<u>125,583,820</u>			
<b>PHARMACEUTICALS - 22.0%</b>					
AbbVie, Inc.	167,273	12,665,911			
Mylan N.V.*	186,140	3,681,849			
Neurocrine Biosciences, Inc.*	34,569	3,115,013			
PRA Health Sciences, Inc.*	28,790	2,856,832			
Sarepta Therapeutics, Inc.*	35,008	2,636,803			
Jazz Pharmaceuticals plc*	18,095	2,318,693			
Global Blood Therapeutics, Inc.*	39,203	1,902,130			
Alkermes plc*	86,740	1,692,297			
Portola Pharmaceuticals, Inc.* <sup>1</sup>	59,290	1,590,158			
Agios Pharmaceuticals, Inc.* <sup>1</sup>	47,498	1,538,935			
Heron Therapeutics, Inc.*	73,120	1,352,720			
Madrigal Pharmaceuticals, Inc.*	14,450	1,245,879			
Clovis Oncology, Inc.* <sup>1</sup>	130,530	512,983			
<b>Total Pharmaceuticals</b>		<u>37,110,203</u>			
			<b>HEALTHCARE-PRODUCTS - 1.9%</b>		
			Bio-Techne Corp.	16,398	\$ 3,208,597
			<b>HEALTHCARE-SERVICES - 1.6%</b>		
			Syneos Health, Inc.*	50,860	2,706,260
			<b>Total Common Stocks</b>		
			(Cost \$88,783,107)		
			<u>168,608,880</u>		
			<b>RIGHTS<sup>†††</sup> - 0.0%</b>		
			<b>BIOTECHNOLOGY – 0.0%</b>		
			Clinical Data, Inc.* <sup>2</sup>	24,000	—
			<b>Total Rights</b>		
			(Cost \$—)		
			<u>—</u>		
			<b>FACE</b>		
			<b>AMOUNT</b>		
			<u>—</u>		
			<b>REPURCHASE AGREEMENTS<sup>†††</sup> - 0.7%</b>		
			JPMorgan Chase & Co.		
			issued 09/30/19 at 2.35%		
			due 10/01/19	\$ 710,572	710,572
			Bank of America Merrill Lynch		
			issued 09/30/19 at 2.28%		
			due 10/01/19	228,496	228,496
			Barclays Capital		
			issued 09/30/19 at 2.00%		
			due 10/01/19	205,647	205,647
			<b>Total Repurchase Agreements</b>		
			(Cost \$1,144,715)		
			<u>1,144,715</u>		
			<b>SHARES</b>		
			<u>—</u>		
			<b>SECURITIES LENDING COLLATERAL<sup>†††</sup> - 4.8%</b>		
			<b>Money Market Fund</b>		
			First American Government		
			Obligations Fund — Class Z, 1.83% <sup>5</sup>		
			8,153,730	8,153,730	
			<b>Total Securities Lending Collateral</b>		
			(Cost \$8,153,730)		
			<u>8,153,730</u>		
			<b>Total Investments - 105.4%</b>		
			(Cost \$98,081,552)		
			<u>\$ 177,907,325</u>		
			<b>Other Assets &amp; Liabilities, net - (5.4%)</b>		
			<u>(9,040,200)</u>		
			<b>Total Net Assets - 100.0%</b>		
			<u>\$ 168,867,125</u>		

**BIOTECHNOLOGY FUND**

\* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

<sup>1</sup> All or a portion of this security is on loan at September 30, 2019.

<sup>2</sup> Security was fair valued by the Valuation Committee at September 30, 2019. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

<sup>3</sup> Repurchase Agreements.

<sup>4</sup> Securities lending collateral.

<sup>5</sup> Rate indicated is the 7-day yield as of September 30, 2019.

ADR — American Depositary Receipt

plc — Public Limited Company